Pulmonary pleomorphic carcinoma with pembrolizumab monotherapy

Adenocarcinoma (ADC) is the most common form of lung cancer; however, some other types of lung cancer can sometimes mimic ADC. It then takes experienced pathologists and special stains to make the correct diagnosis. Here, we present a patient with pulmonary pleomorphic carcinoma who was misdiagnosed...

Descripción completa

Detalles Bibliográficos
Autores principales: Chang, Hao‐Chun, Hsu, Chia‐Lin, Chang, Yih‐Leong, Yu, Chong‐Jen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons, Ltd 2020
Materias:
Case Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7290282/
https://www.ncbi.nlm.nih.gov/pubmed/32547767
http://dx.doi.org/10.1002/rcr2.597
_version_ 1783545639417675776
author Chang, Hao‐Chun
Hsu, Chia‐Lin
Chang, Yih‐Leong
Yu, Chong‐Jen
author_facet Chang, Hao‐Chun
Hsu, Chia‐Lin
Chang, Yih‐Leong
Yu, Chong‐Jen
author_sort Chang, Hao‐Chun
collection PubMed
description Adenocarcinoma (ADC) is the most common form of lung cancer; however, some other types of lung cancer can sometimes mimic ADC. It then takes experienced pathologists and special stains to make the correct diagnosis. Here, we present a patient with pulmonary pleomorphic carcinoma who was misdiagnosed with ADC, and was treated with pembrolizumab for 13 months. The diagnosis and treatment (including immunotherapy) are also reviewed.
format Online
Article
Text
id pubmed-7290282
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher John Wiley & Sons, Ltd
record_format MEDLINE/PubMed
spelling pubmed-72902822020-06-15 Pulmonary pleomorphic carcinoma with pembrolizumab monotherapy Chang, Hao‐Chun Hsu, Chia‐Lin Chang, Yih‐Leong Yu, Chong‐Jen Respirol Case Rep Case Reports Adenocarcinoma (ADC) is the most common form of lung cancer; however, some other types of lung cancer can sometimes mimic ADC. It then takes experienced pathologists and special stains to make the correct diagnosis. Here, we present a patient with pulmonary pleomorphic carcinoma who was misdiagnosed with ADC, and was treated with pembrolizumab for 13 months. The diagnosis and treatment (including immunotherapy) are also reviewed. John Wiley & Sons, Ltd 2020-06-12 /pmc/articles/PMC7290282/ /pubmed/32547767 http://dx.doi.org/10.1002/rcr2.597 Text en © 2020 The Authors. Respirology Case Reports published by John Wiley & Sons Australia, Ltd on behalf of The Asian Pacific Society of Respirology This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
spellingShingle Case Reports
Chang, Hao‐Chun
Hsu, Chia‐Lin
Chang, Yih‐Leong
Yu, Chong‐Jen
Pulmonary pleomorphic carcinoma with pembrolizumab monotherapy
title Pulmonary pleomorphic carcinoma with pembrolizumab monotherapy
title_full Pulmonary pleomorphic carcinoma with pembrolizumab monotherapy
title_fullStr Pulmonary pleomorphic carcinoma with pembrolizumab monotherapy
title_full_unstemmed Pulmonary pleomorphic carcinoma with pembrolizumab monotherapy
title_short Pulmonary pleomorphic carcinoma with pembrolizumab monotherapy
title_sort pulmonary pleomorphic carcinoma with pembrolizumab monotherapy
topic Case Reports
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7290282/
https://www.ncbi.nlm.nih.gov/pubmed/32547767
http://dx.doi.org/10.1002/rcr2.597
work_keys_str_mv AT changhaochun pulmonarypleomorphiccarcinomawithpembrolizumabmonotherapy
AT hsuchialin pulmonarypleomorphiccarcinomawithpembrolizumabmonotherapy
AT changyihleong pulmonarypleomorphiccarcinomawithpembrolizumabmonotherapy
AT yuchongjen pulmonarypleomorphiccarcinomawithpembrolizumabmonotherapy

Ejemplares similares